• 简

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Collegium Pharmaceutical (COLL) Draws Fresh Valuation Attention, Is It Still A Bargain?

    Simply Wall St·07/12/2026 02:18:40
    语音播报

    Collegium Pharmaceutical (COLL) has drawn fresh interest after recent trading left the stock at about $35.23, with returns mixed across different time frames and investors reassessing how its pain management portfolio supports the current valuation.

    See our latest analysis for Collegium Pharmaceutical.

    The recent dip in Collegium Pharmaceutical's share price, with a 1-day share price return of 1.62% down and a 7-day share price return of 4.86% down, sits against a mixed picture where the year-to-date share price return is 22.62% down, but the 1-year total shareholder return is 8.33% and the 3-year total shareholder return is 63.03%. This suggests that longer term holders have seen stronger results than those focused on recent trading.

    If you are reassessing your watchlist after Collegium Pharmaceutical's recent moves, this could be a good moment to broaden your search with 41 healthcare AI stocks.

    So after a pullback that still leaves Collegium Pharmaceutical well ahead over three and five years, is most of the easy upside already in the rearview mirror, or does the current price still leave clear room for value?

    Most Popular Narrative: 35.2% Undervalued

    Based on the most followed narrative, Collegium Pharmaceutical's fair value sits at $54.33 per share, well above the recent $35.23 close. This frames the current debate around how much of its pain and ADHD earnings story is already reflected in the price.

    Collegium's disciplined capital allocation and ongoing business development (M&A) strategy, including pursuing synergistic pain/CNS assets, is expected to drive portfolio diversification and inorganic growth, further reducing revenue concentration risk and providing additional sources of EBITDA and earnings stability.

    Read the complete narrative. Read the complete narrative.

    Want to see what is behind that confidence in future earnings power? The narrative leans on a tight mix of revenue growth, rising margins and a lower future earnings multiple. The combination paints a very specific path between today’s profits and that $54.33 figure, and the details might challenge what you currently expect for Collegium Pharmaceutical.

    Result: Fair Value of $54.33 (UNDERVALUED)

    Have a read of the narrative in full and understand what's behind the forecasts.

    However, that upside narrative for Collegium Pharmaceutical still leans heavily on a concentrated pain portfolio and assumes that regulatory or pricing pressures do not materially squeeze margins.

    Find out about the key risks to this Collegium Pharmaceutical narrative.

    Next Steps

    With sentiment on Collegium Pharmaceutical split between concern and optimism, this is a good time to review the data directly, weigh both sides, and decide how it fits your portfolio given the 4 key rewards and 2 important warning signs.

    Looking for more investment ideas beyond Collegium Pharmaceutical?

    If Collegium Pharmaceutical is already on your radar, do not stop there. Broaden your opportunity set with a few focused stock ideas built from clear fundamentals.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.